At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VTYX Ventyx Biosciences, Inc.
Market Closed 01-03 16:00:00 EST
2.49
+0.35
+16.36%
盘后2.50
+0.01+0.40%
19:46 EST
High2.56
Low2.14
Vol2.97M
Open2.14
D1 Closing2.14
Amplitude19.63%
Mkt Cap176.07M
Tradable Cap122.44M
Total Shares70.71M
T/O7.17M
T/O Rate6.04%
Tradable Shares49.17M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.